Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decrease in Short Interest

Chimerix, Inc. (NASDAQ:CMRX) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 710,300 shares, a decline of 53.3% from the October 31st total of 1,520,000 shares. Based on an average daily volume of 197,100 shares, the short-interest ratio is presently 3.6 days. Approximately 0.9% of the company’s shares are sold short.

Chimerix Trading Up 0.1 %

Shares of CMRX stock traded up $0.00 on Thursday, hitting $0.91. The stock had a trading volume of 78,394 shares, compared to its average volume of 347,557. The firm has a market cap of $81.40 million, a P/E ratio of -0.96 and a beta of 1.13. Chimerix has a twelve month low of $0.75 and a twelve month high of $1.30. The company has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $0.91.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new stake in shares of Chimerix during the second quarter worth about $137,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Finally, Valeo Financial Advisors LLC raised its holdings in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares during the period. 45.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on CMRX shares. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Monday, November 11th. Finally, Wedbush reissued an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Monday, November 18th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.